Avidity Biosciences Inc. is a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), a novel class of RNA therapeutics that combine the specificity of monoclonal antibodies with the precision of oligonucleotides to target hard-to-reach tissues like skeletal and cardiac muscle. This proprietary AOC platform enables targeted delivery of RNA-modulating therapies directly into cells, addressing the root causes of diseases previously challenging for existing RNA treatments. The company focuses on rare neuromuscular diseases, including myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD), with multiple programs in clinical development. Avidity Biosciences Inc. also advances initiatives in precision cardiology and immunology through internal discovery efforts and partnerships. Headquartered in San Diego, California, the company operates within the pharmaceutical preparation manufacturing segment, emphasizing innovative solutions for patients with unmet medical needs in muscle disease franchises and beyond.